Literature DB >> 36259466

Earlier continuous renal replacement therapy is associated with reduced mortality in rhabdomyolysis patients.

Xiayin Li1,2, Ming Bai2, Yan Yu2, Feng Ma2, Lijuan Zhao2, Yajuan Li2, Hao Wu2, Lei Zhou3, Shiren Sun2.   

Abstract

BACKGROUND: Continuous renal replacement therapy (CRRT) is commonly employed for rhabdomyolysis (RM) patients. However, the optimal initiation timing of CRRT and prognostic factors were not well evaluated for patients with RM. We aimed to investigate the efficacy of CRRT timing on mortality and the risk factors for death in RM patients who received CRRT.
METHODS: RM patients who received CRRT between 1 May 2010 and 31 May 2021 in our center were retrospectively included. Univariate and multivariate logistic analyses were performed to identify the risk factors for primary outcome (90-day mortality).
RESULTS: A total of 134 patients were included in our study. The 90-day mortality rate was 38.06%. The median time from CRRT initiation to peak CK occurrence was 4.8 h (IQR -16, 14), 67 patients received CRRT before 4.8 h after peak CK occurrence (early CRRT), and 67 patients received CRRT beyond 4.8 h after peak CK occurrence (late CRRT). Multivariate logistic regression analysis showed that the time from CRRT initiation to the peak CK (per 1 h, OR 1.026, 95% CI 1.004-1.049, p = 0.023), late CRRT (OR 3.082, 95% CI 1.072-8.859, p = 0.037), elevated serum cardiac troponin I (cTnI) (per 1 ng/mL, OR 1.218, 95% CI 1.011-1.468, p = 0.038), older age (per 1 year, OR 1.042, 95% CI 1.003-1.081, p = 0.032), and need of mechanical ventilation support (OR 4.632, 95% CI 1.292-16.61, p = 0.019) were independent risk factors for 90-day mortality.
CONCLUSIONS: Earlier CRRT initiation before 4.8 h after peak CK occurrence was associated with lower 90-day patient mortality.

Entities:  

Keywords:  Rhabdomyolysis; acute kidney injury; continue renal replacement therapy; creatine kinase; mortality

Mesh:

Substances:

Year:  2022        PMID: 36259466      PMCID: PMC9586620          DOI: 10.1080/0886022X.2022.2132170

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   3.222


  58 in total

1.  Mediators of the Impact of Hourly Net Ultrafiltration Rate on Mortality in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.

Authors:  Thummaporn Naorungroj; Ary Serpa Neto; Lara Zwakman-Hessels; Yanase Fumitaka; Glenn Eastwood; Raghavan Murugan; John A Kellum; Rinaldo Bellomo
Journal:  Crit Care Med       Date:  2020-10       Impact factor: 7.598

2.  A risk prediction score for kidney failure or mortality in rhabdomyolysis.

Authors:  Gearoid M McMahon; Xiaoxi Zeng; Sushrut S Waikar
Journal:  JAMA Intern Med       Date:  2013-10-28       Impact factor: 21.873

Review 3.  Rhabdomyolysis.

Authors:  Janice L Zimmerman; Michael C Shen
Journal:  Chest       Date:  2013-09       Impact factor: 9.410

4.  Myoglobin clearance and removal during continuous venovenous hemofiltration.

Authors:  S L Amyot; M Leblanc; Y Thibeault; D Geadah; J Cardinal
Journal:  Intensive Care Med       Date:  1999-10       Impact factor: 17.440

5.  Rhabdomyolysis: a 10-year retrospective study of patients treated in a medical department.

Authors:  Marie Vangstad; Mari A Bjornaas; Dag Jacobsen
Journal:  Eur J Emerg Med       Date:  2019-06       Impact factor: 2.799

Review 6.  Strategies for the optimal timing to start renal replacement therapy in critically ill patients with acute kidney injury.

Authors:  Sean M Bagshaw; Ron Wald
Journal:  Kidney Int       Date:  2017-02-17       Impact factor: 10.612

7.  Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial.

Authors:  Alexander Zarbock; John A Kellum; Christoph Schmidt; Hugo Van Aken; Carola Wempe; Hermann Pavenstädt; Andreea Boanta; Joachim Gerß; Melanie Meersch
Journal:  JAMA       Date:  2016 May 24-31       Impact factor: 56.272

8.  Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.

Authors:  Shigehiko Uchino; Rinaldo Bellomo; Hiroshi Morimatsu; Stanislao Morgera; Miet Schetz; Ian Tan; Catherine Bouman; Ettiene Macedo; Noel Gibney; Ashita Tolwani; Heleen Oudemans-van Straaten; Claudio Ronco; John A Kellum
Journal:  Intensive Care Med       Date:  2007-06-27       Impact factor: 17.440

9.  Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis.

Authors:  Saber D Barbar; Raphaël Clere-Jehl; Abderrahmane Bourredjem; Romain Hernu; Florent Montini; Rémi Bruyère; Christine Lebert; Julien Bohé; Julio Badie; Jean-Pierre Eraldi; Jean-Philippe Rigaud; Bruno Levy; Shidasp Siami; Guillaume Louis; Lila Bouadma; Jean-Michel Constantin; Emmanuelle Mercier; Kada Klouche; Damien du Cheyron; Gaël Piton; Djillali Annane; Samir Jaber; Thierry van der Linden; Gilles Blasco; Jean-Paul Mira; Carole Schwebel; Loïc Chimot; Philippe Guiot; Mai-Anh Nay; Ferhat Meziani; Julie Helms; Claire Roger; Benjamin Louart; Remi Trusson; Auguste Dargent; Christine Binquet; Jean-Pierre Quenot
Journal:  N Engl J Med       Date:  2018-10-11       Impact factor: 91.245

10.  Association of Net Ultrafiltration Rate With Mortality Among Critically Ill Adults With Acute Kidney Injury Receiving Continuous Venovenous Hemodiafiltration: A Secondary Analysis of the Randomized Evaluation of Normal vs Augmented Level (RENAL) of Renal Replacement Therapy Trial.

Authors:  Raghavan Murugan; Samantha J Kerti; Chung-Chou H Chang; Martin Gallagher; Gilles Clermont; Paul M Palevsky; John A Kellum; Rinaldo Bellomo
Journal:  JAMA Netw Open       Date:  2019-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.